These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
517 related articles for article (PubMed ID: 22760226)
1. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226 [TBL] [Abstract][Full Text] [Related]
2. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer. Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696 [TBL] [Abstract][Full Text] [Related]
3. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib. Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429 [TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670 [TBL] [Abstract][Full Text] [Related]
6. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503 [TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Umemura S; Tsubouchi K; Yoshioka H; Hotta K; Takigawa N; Fujiwara K; Horita N; Segawa Y; Hamada N; Takata I; Yamane H; Kamei H; Kiura K; Tanimoto M Lung Cancer; 2012 Jul; 77(1):134-9. PubMed ID: 22487432 [TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626 [TBL] [Abstract][Full Text] [Related]
10. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159 [TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039 [TBL] [Abstract][Full Text] [Related]
12. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations. Koyama N; Uchida Y Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153 [TBL] [Abstract][Full Text] [Related]
14. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614 [TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465 [TBL] [Abstract][Full Text] [Related]
16. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236 [TBL] [Abstract][Full Text] [Related]
17. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation. Koo DH; Kim KP; Choi CM; Lee DH; Lee JC; Lee JS; Jang SJ; Kim SW Cancer Chemother Pharmacol; 2015 Jan; 75(1):197-206. PubMed ID: 25422153 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation. Imai H; Shukuya T; Takahashi T; Fujiwara S; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Harada H; Endo M; Nakajima T; Yamamoto N Anticancer Res; 2013 Aug; 33(8):3279-84. PubMed ID: 23898092 [TBL] [Abstract][Full Text] [Related]
19. Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer. Fukihara J; Watanabe N; Taniguchi H; Kondoh Y; Kimura T; Kataoka K; Matsuda T; Yokoyama T; Hasegawa Y Oncology; 2014; 86(2):86-93. PubMed ID: 24457318 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug. Lee Y; Kim HY; Lee SH; Lim KY; Lee GK; Yun T; Han JY; Kim HT; Lee JS Clin Lung Cancer; 2014 Mar; 15(2):145-51. PubMed ID: 24342626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]